Do analysts recommend MOR or SMMT?

Summit Therapeutics has a consensus target price of $26.97, suggesting a potential upside of 74.92%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Summit Therapeutics 2 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.44

Does the media refer more to MOR or SMMT?

In the previous week, Summit Therapeutics had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Summit Therapeutics and 1 mentions for MorphoSys. Summit Therapeutics' average media sentiment score of 0.86 beat MorphoSys' score of -0.71 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MOR or KRYS?

Krystal Biotech has a consensus price target of $340.56, suggesting a potential downside of 9.20%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83

Which has preferable valuation & earnings, MOR or KRYS?

Krystal Biotech has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Krystal Biotech $389.13M 28.41 $204.83M $7.48 50.14

Is MOR or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to MorphoSys' net margin of -226.79%. Krystal Biotech's return on equity of 19.25% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Krystal Biotech 53.92% 19.25% 17.62%

Does the media prefer MOR or KRYS?

In the previous week, Krystal Biotech had 4 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Krystal Biotech and 1 mentions for MorphoSys. Krystal Biotech's average media sentiment score of 1.28 beat MorphoSys' score of -0.71 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Krystal Biotech 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MOR or ABVX?

Abivax has a consensus target price of $146.00, suggesting a potential upside of 0.93%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Abivax 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.81

Which has preferable earnings & valuation, MOR or ABVX?

MorphoSys has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is MOR or ABVX more profitable?

Abivax has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Abivax's return on equity of -99.02% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Abivax N/A -99.02% -70.26%

Does the media refer more to MOR or ABVX?

In the previous week, Abivax had 36 more articles in the media than MorphoSys. MarketBeat recorded 37 mentions for Abivax and 1 mentions for MorphoSys. Abivax's average media sentiment score of 0.57 beat MorphoSys' score of -0.71 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Abivax 12 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CYTK or MOR?

Cytokinetics currently has a consensus price target of $100.00, indicating a potential upside of 15.62%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cytokinetics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.91 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, CYTK or MOR?

MorphoSys has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 122.24 -$784.96M -$6.84 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is CYTK or MOR more profitable?

MorphoSys has a net margin of -226.79% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% MorphoSys -226.79% -694.31% -22.55%

Does the media prefer CYTK or MOR?

In the previous week, Cytokinetics had 15 more articles in the media than MorphoSys. MarketBeat recorded 16 mentions for Cytokinetics and 1 mentions for MorphoSys. Cytokinetics' average media sentiment score of 0.16 beat MorphoSys' score of -0.71 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate NUVL or MOR?

Nuvalent presently has a consensus target price of $127.73, indicating a potential upside of 3.23%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts plainly believe Nuvalent is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 15 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.15 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, NUVL or MOR?

MorphoSys has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is NUVL or MOR more profitable?

Nuvalent has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Nuvalent's return on equity of -40.11% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% MorphoSys -226.79% -694.31% -22.55%

Does the media prefer NUVL or MOR?

In the previous week, Nuvalent had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Nuvalent and 1 mentions for MorphoSys. Nuvalent's average media sentiment score of 0.64 beat MorphoSys' score of -0.71 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

MorphoSys (MOR) Competitors

$18.96 0.00 (0.00%)

As of 07/2/2026

Compare

MOR vs. SMMT, KRYS, ABVX, CYTK, and NUVL

Should you buy MorphoSys stock or one of its competitors? MarketBeat compares MorphoSys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MorphoSys include Summit Therapeutics (SMMT), Krystal Biotech (KRYS), Abivax (ABVX), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does MorphoSys compare to Summit Therapeutics?

MorphoSys (NASDAQ:MOR) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Summit Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Summit Therapeutics' return on equity of -291.24% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Summit Therapeutics	N/A	-291.24%	-243.07%

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

In the previous week, Summit Therapeutics had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Summit Therapeutics and 1 mentions for MorphoSys. Summit Therapeutics' average media sentiment score of 0.86 beat MorphoSys' score of -0.71 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summit Therapeutics has a consensus target price of $26.97, suggesting a potential upside of 74.92%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

MorphoSys has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Summary

Summit Therapeutics beats MorphoSys on 10 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Krystal Biotech?

MorphoSys (NASDAQ:MOR) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Krystal Biotech has a net margin of 53.92% compared to MorphoSys' net margin of -226.79%. Krystal Biotech's return on equity of 19.25% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Krystal Biotech had 4 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Krystal Biotech and 1 mentions for MorphoSys. Krystal Biotech's average media sentiment score of 1.28 beat MorphoSys' score of -0.71 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Krystal Biotech	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Krystal Biotech	$389.13M	28.41	$204.83M	$7.48	50.14

Krystal Biotech has a consensus price target of $340.56, suggesting a potential downside of 9.20%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats MorphoSys on 15 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Abivax?

MorphoSys (NASDAQ:MOR) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Abivax has a consensus target price of $146.00, suggesting a potential upside of 0.93%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

MorphoSys has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Abivax has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Abivax's return on equity of -99.02% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Abivax	N/A	-99.02%	-70.26%

In the previous week, Abivax had 36 more articles in the media than MorphoSys. MarketBeat recorded 37 mentions for Abivax and 1 mentions for MorphoSys. Abivax's average media sentiment score of 0.57 beat MorphoSys' score of -0.71 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Abivax	12 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Abivax beats MorphoSys on 8 of the 15 factors compared between the two stocks.

How does MorphoSys compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

MorphoSys has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	122.24	-$784.96M	-$6.84	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Cytokinetics currently has a consensus price target of $100.00, indicating a potential upside of 15.62%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cytokinetics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

18.4% of MorphoSys shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

In the previous week, Cytokinetics had 15 more articles in the media than MorphoSys. MarketBeat recorded 16 mentions for Cytokinetics and 1 mentions for MorphoSys. Cytokinetics' average media sentiment score of 0.16 beat MorphoSys' score of -0.71 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

MorphoSys has a net margin of -226.79% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

Cytokinetics beats MorphoSys on 9 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

MorphoSys has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Nuvalent has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

In the previous week, Nuvalent had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Nuvalent and 1 mentions for MorphoSys. Nuvalent's average media sentiment score of 0.64 beat MorphoSys' score of -0.71 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nuvalent has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Nuvalent's return on equity of -40.11% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
MorphoSys	-226.79%	-694.31%	-22.55%

Nuvalent presently has a consensus target price of $127.73, indicating a potential upside of 3.23%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts plainly believe Nuvalent is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nuvalent beats MorphoSys on 9 of the 15 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOR vs. The Competition

Export

Metric	MorphoSys	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.86B	$792.30M	$7.18B	$12.47B
Dividend Yield	N/A	4.84%	2.67%	6.50%
P/E Ratio	-5.45	1.66	28.02	24.70
Price / Sales	11.99	116.91	532.59	98.61
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	54.17	8.17	10.96	6.46
Net Income	-$205.35M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

MorphoSys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730	News Coverage
SMMT Summit Therapeutics	3.8936 of 5 stars	$14.38 -1.3%	$26.97 +87.6%	-36.7%	$11.31B	N/A	N/A	110	Analyst Upgrade Gap Down
KRYS Krystal Biotech	2.5462 of 5 stars	$371.58 0.0%	$340.56 -8.3%	+162.3%	$10.96B	$389.13M	49.68	210	Positive News Analyst Downgrade
ABVX Abivax	1.4168 of 5 stars	$132.56 -0.5%	$144.46 +9.0%	+1,714.9%	$10.63B	N/A	N/A	61	Trending News Analyst Forecast Gap Down
CYTK Cytokinetics	2.7242 of 5 stars	$85.26 +0.1%	$100.00 +17.3%	+155.1%	$10.60B	$88.04M	N/A	250	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Competitors

MOR vs. SMMT, KRYS, ABVX, CYTK, and NUVL

How does MorphoSys compare to Summit Therapeutics?

Summary

How does MorphoSys compare to Krystal Biotech?

Summary

How does MorphoSys compare to Abivax?

Summary

How does MorphoSys compare to Cytokinetics?

Summary

How does MorphoSys compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MorphoSys (MOR) Competitors

MOR vs. SMMT, KRYS, ABVX, CYTK, and NUVL

How does MorphoSys compare to Summit Therapeutics?

Is MOR or SMMT more profitable?

Which has more volatility and risk, MOR or SMMT?

Does the media refer more to MOR or SMMT?

Do institutionals & insiders hold more shares of MOR or SMMT?

Do analysts recommend MOR or SMMT?

Which has preferable valuation & earnings, MOR or SMMT?

Summary

How does MorphoSys compare to Krystal Biotech?

Is MOR or KRYS more profitable?

Does the media prefer MOR or KRYS?

Which has preferable valuation & earnings, MOR or KRYS?

Do analysts prefer MOR or KRYS?

Which has more volatility and risk, MOR or KRYS?

Do insiders & institutionals hold more shares of MOR or KRYS?

Summary

How does MorphoSys compare to Abivax?

Do analysts rate MOR or ABVX?

Which has preferable earnings & valuation, MOR or ABVX?

Do insiders and institutionals hold more shares of MOR or ABVX?

Which has more volatility and risk, MOR or ABVX?

Is MOR or ABVX more profitable?

Does the media refer more to MOR or ABVX?

Summary

How does MorphoSys compare to Cytokinetics?

Which has stronger valuation and earnings, CYTK or MOR?

Do analysts recommend CYTK or MOR?

Do institutionals and insiders believe in CYTK or MOR?

Which has more volatility & risk, CYTK or MOR?

Does the media prefer CYTK or MOR?

Is CYTK or MOR more profitable?

Summary

How does MorphoSys compare to Nuvalent?

Which has preferable earnings & valuation, NUVL or MOR?

Which has more volatility and risk, NUVL or MOR?

Does the media prefer NUVL or MOR?

Do insiders and institutionals believe in NUVL or MOR?

Is NUVL or MOR more profitable?

Do analysts rate NUVL or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools